Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
The Safety Monitoring Committee has recommended to continue the trial without modifications as the futility boundary was successfully passed.